© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Chemists in the mid-twentieth century spent years probing for new ways to treat mental health issues and cardiovascular conditions. In the process of synthesizing monoamine oxidase inhibitors (MAOIs), pargyline appeared as a remarkable compound, first brought into circulation in the late 1960s. Smith, Kline & French included it under the trade name Eutonyl, capitalizing on pargyline’s ability to slow the breakdown of neurotransmitters. Medical professionals welcomed it as a step forward in managing depression and hypertension—offering more options before the newer classes of antidepressants and antihypertensives swept the market. Despite its decline in clinical popularity after reports of side effects and dietary restrictions, pargyline holds an important place in pharmaceutical progress and is now a key reference point in the development of modern neuropsychiatric drugs.
Pargyline hydrochloride stands as a crystalline, water-soluble salt used primarily in research settings today. Labs utilize it for its ability to inhibit the enzyme monoamine oxidase B (MAO-B), which helps regulate neurotransmitters in the brain such as dopamine and serotonin. Its activity profile has made it relevant not just in psychiatric research, but also in studying neurodegeneration, cancer metabolism, and even as a comparative agent in antihypertensive therapy. While its use in direct patient care dropped over the years, pargyline maintains an active role in exploring new frontiers in neuropharmacology and molecular biology, with suppliers offering pharmaceutical-grade material to universities and biotechs.
Pargyline hydrochloride comes as a white to off-white powder, showing stability under standard storage conditions. Its molecular formula is C11H14ClN, resulting in a molecular weight around 195.7 g/mol. It dissolves freely in water and alcohol, less so in nonpolar solvents; this solubility shapes its application in both in vivo and in vitro research. The melting range sits comfortably between 168–172°C, and the compound retains stability if kept away from strong light or moisture. Nearly odorless, with a slightly bitter taste, this compound’s crystalline structure makes it easy to weigh and compound in laboratory experiments.
Reliable product batches arrive with labeling that details concentration, lot number, synthesis date, and purity—usually fine-tuned up to 98% or higher by HPLC or NMR verification. Safety sheets pinpoint the CAS number 555-57-7 and recommend storage in cool, dry places. Regulatory compliance statements and transport guidelines line up with international standards, since pargyline’s hazards involve handling precautions similar to most research chemicals. Clear, unambiguous details on product provenance improve traceability for researchers and reinforce trust in the chemical’s quality.
Most pargyline hydrochloride found in laboratories today gets synthesized through alkylation of N-methylbenzylamine with 4-chlorobutyronitrile. After forming the base pargyline, conversion to the hydrochloride salt typically follows a controlled acidification step, where hydrogen chloride gas gets bubbled through the dissolved free base. After thorough purification, usually involving recrystallization from ethanol or acetone, the compound reaches a fine, consistent texture ready for use in pharmacological research. These tried-and-tested synthetic methods allow for scale-up, essential for supplying academic and pharmaceutical demands around the world.
Pargyline acts as a substrate and inhibitor in a range of chemical assays. MAO-B interacts with it irreversibly—the molecule binds to the flavin adenine dinucleotide (FAD) cofactor in the enzyme, blocking neurotransmitter breakdown. Chemists also experiment with structural analogs, changing side chains to discover new MAO inhibitors or agents targeting metabolic pathways in cancer. It undergoes N-demethylation and other biotransformations in vivo, generating metabolites with distinct pharmacological actions, which expand insight into its behavior and potential off-target effects.
The compound’s primary names include pargyline hydrochloride and its free base, pargyline. Industry insiders and scientific papers also connect it to the code SKF-385, 555-57-7, and Eutonyl in clinical contexts. Universal Drug Identification Numbers (UNII) and multiple foreign language references reflect its history as both a prescription medicine and a probe in lab-based models across pharmacology and neuroscience. These synonyms ensure researchers locate the proper chemical and distinguish it from related MAOIs.
Pargyline hydrochloride demands careful use. Contact with skin or eyes can cause irritation. Inhalation and ingestion raise more serious risks due to its impact on monoamine metabolism; accidental exposure can even provoke serotonin syndrome or blood pressure variation. Safety documentation calls for gloves, eye protection, and fume hoods, echoing personal experience in the lab where even brief lapses—like using powder near open containers—sometimes trigger cautionary tales or disciplinary action. Disposal guidelines align with environmental health directives, sending waste to high-temperature incineration. Compliance with OSHA and ISO workplace requirements reassures all team members of minimized risk during handling and transfer, which proves critical for both short-term safety and long-term well-being.
While doctors rarely prescribe pargyline anymore, its value grows in research. Scientists apply it as a tool to dissect dopamine signaling and explore Parkinson’s disease pathology. MAO-B inhibition by pargyline makes it a preferred compound for modeling neuroprotection and dissecting the blood-brain barrier’s influences on drug transport. In cancer labs, investigators probe its role in mitochondrial metabolism and cell signaling, using it to spotlight potential targets for anti-tumor strategies. Its mechanisms even interest cardiovascular researchers, especially those untangling the triggers behind drug-induced hypertension.
Chasing insight into both therapeutic and side effect profiles, researchers worldwide continue to revisit pargyline and its relatives. Teams mix classic bench science—like binding affinity assays and tissue culture—with in vivo imaging and molecular modeling. Its influence on oxidative stress, inflammation, and dopamine metabolism remains central in neurodegeneration studies. An uptick in funding for precision medicine encourages fresh takes on old drugs, so even compounds like pargyline find renewed relevance in modern clinical trial designs and translational medicine. Commercial efforts also include packaging and stability enhancements to meet the expanding needs of more advanced experiments and regulatory frameworks.
Toxicologists warn that even moderate doses can trigger orthostatic hypotension, agitation, and dangerous drug interactions with foods or medications containing tyramine. Early reports of severe hypertension, headaches, and risk of serotonin syndrome explain why doctors backed away from prescribing it to the average patient. Animal studies continue to yield data on acute and chronic exposure, providing reference doses for safe handling in research settings. Recent efforts also prioritize screening for off-target effects, exploring toxicity profiles in both mature and developing organisms. Researchers learn to respect its potent influence instead of underestimating potential harm just because it operates at low concentrations.
Interest in MAO inhibitors sees a resurgence thanks to new discoveries in neuroprotection, psychiatric care, and metabolic disorders. Pargyline earns attention in over 100 active patents and research projects each year, as investigators try to harness the lessons of the past for the promise of future therapies. With the expanding toolkit of neurobiological methods, possibilities arise to combine classic drugs with targeted delivery systems or gene editing approaches, reducing unwanted side effects and reviving therapeutic potential. Its role as a reference MAO-B inhibitor endures, anchoring assay development and research innovation that echoes far beyond the chemistry lab—touching clinical medicine, biotechnology, and the slow, persistent drive to improve patient care.
Pargyline Hydrochloride doesn’t show up in conversations about modern drug cabinets, but this medication played a strong role back in the day for people living with high blood pressure. Doctors prescribed pargyline hydrochloride as an antihypertensive. Its main job: help patients keep blood pressure numbers in check. The medical community now tends to go for other solutions, but understanding pargyline’s story gives us a lens into how medicine evolves and what it means for those searching for better options.
Pargyline stands in a category called monoamine oxidase inhibitors (MAOIs). Unlike the antidepressant use that comes to mind with MAOIs, pargyline targeted blood pressure by blocking enzymes that break down certain chemicals in the body. This action helped widen blood vessels. Wider vessels meant less pressure on artery walls, which in turn brought the blood pressure number closer to safer levels. If you’ve ever seen a family member struggle with hypertension, you know how crucial blood flow control can be. Uncontrolled hypertension creeps up with risks for heart attack, stroke, and kidney damage. Doctors back in the day were always looking for ways to prevent those life-altering events, and pargyline was part of their toolkit.
In the pharmacy today, you don’t see pargyline prescribed much. Safer and more effective blood pressure medications now fill that spot: ACE inhibitors, beta blockers, diuretics, and calcium channel blockers. People who take these modern medications often experience fewer interactions, lighter side effects, and better overall health outcomes.
Pargyline hydrochloride as an MAOI brought some real challenges in the kitchen, too. Patients worried about what foods might trigger a spike or a drop in pressure. Eating foods high in tyramine—think aged cheese, cured meats, and certain beans—could set off dangerous reactions, sometimes tipping the scales toward a hypertension crisis. For folks trying to enjoy a social meal or a family gathering, these restrictions weighed heavy. Modern options mean fewer food worries and less risk of complications.
Knowing pargyline’s story matters because it shows how the field moves with research and real-world experience. Drug recalls or discontinued use don’t always stem from danger, but often from progress. Big leaps forward in medical science push older options aside, but that doesn’t erase the importance of those early treatments for previous generations. It’s worth learning how older drugs worked, what risks they carried, and why newer medicines now take the spotlight.
Every new pill added to pharmacy shelves brings the promise of better health with fewer drawbacks. Yet, it’s the lived experience of patients, their families, and their doctors that shapes what we call safe and effective medicine. My own relatives, years ago, relied on medications that demanded attention to the smallest detail, including what food they ate. Today’s choices come with their own benefits and risks, but most of us can sit down to dinner without a second thought about cheese causing problems.
The story of pargyline underscores the need to keep investigating, questioning, and talking about daily life on any prescription, not just the label on the bottle. Science keeps moving, thankfully, and the wisdom gained from medications like pargyline guides decisions for patients and healthcare providers long after the drug steps off the main stage.
Pargyline hydrochloride hits the shelves as a medication for high blood pressure. Doctors started using it decades ago—back when treatment options looked a lot slimmer—by counting on its ability to block certain enzymes that break down neurotransmitters. It gets the job done, but comes with a history of raising more questions than answers because of safety concerns and side effects.
Taking Pargyline brings a list of problems that can really shake up a person’s routine. Some people notice dizziness, which isn’t just bothersome—it risks falls and accidents. Others struggle with headaches, dry mouth, or sleep trouble, all of which put a dent in daily focus and mood. Nausea and gastrointestinal discomfort often come up after a few doses, and that can push folks to skip meals or water, making health worse in the long run.
One of the more serious problems: Pargyline can trigger an abrupt drop in blood pressure when standing up. Somebody on this medication might rise from their chair thinking about chores and instead wind up so lightheaded they need to sit back down. Orthostatic hypotension isn’t just unpleasant—it has led to fainting spells. That’s a huge deal for people who already have health or mobility issues at home.
Pargyline hydrochloride stacks up risks through interactions with everyday foods and common prescription drugs. It acts as a monoamine oxidase inhibitor (MAOI), which means cheese, smoked meats, and soy products can actually cause blood pressure to skyrocket when paired with it. I’ve had to sift through restaurant menus and ask grocery store workers lots of questions with family members on MAOIs like this. If somebody overlooks these dietary needs, they’re rolling the dice on a potentially life-threatening spike in blood pressure, known as hypertensive crisis.
Mixing this drug with antidepressants or certain over-the-counter cough medicines can do more harm than good. Those combinations pump up serotonin to dangerous levels or disrupt heart rhythms, both of which could land a person in the emergency room if the warning signs go ignored. There’s no substitute for open talks with a pharmacist or doctor before adding anything new to the medicine cabinet.
Over the months, the side effects don’t fade back into the background. Instead, things like sexual dysfunction, weight gain, or even swelling of the lower legs can crop up. People living with depression, anxiety, or memory troubles may find those symptoms stick around or get worse. I remember a relative battling mood shifts connected to older blood pressure pills—something the modern generation of hypertension medications works to avoid.
Doctors have gradually moved away from pargyline as more precise, safer blood pressure drugs came along. That doesn’t mean everyone who fills a prescription faces trouble, but it proves the importance of regular check-ins and honest conversations. Anyone who starts or stops a medicine like this without speaking up or understanding the risks stands on shaky ground.
Safer, more effective alternatives exist now: ACE inhibitors, beta blockers, and newer classes bring fewer risks of food interactions or strange side effects. Healthcare professionals should balance benefits with these risks, stay vigilant about drug and food combinations, and look at a patient’s full picture—diet, lifestyle, and everything else.
Though pargyline hydrochloride holds a place in medical history, its side effect profile leaves most doctors and patients looking at other choices to control blood pressure and keep life running smoothly.
Following directions for any medicine beats guessing. Skipping steps or winging it can spell trouble, especially with older drugs like Pargyline Hydrochloride. This medication carved its reputation out treating high blood pressure. It comes from the family of monoamine oxidase inhibitors (MAOIs), which change how nerves handle certain chemicals, including serotonin, dopamine, and norepinephrine.
My neighbor took an MAOI years ago. The warnings felt intimidating — and for good reason. He told me how every dose had to fit smoothly with meals, with plenty of food off-limits. I saw how closely he worked with his doctor. Those lessons stuck with me: medicines like this pack punch. Small slip-ups can cause real harm.
Doctors usually ask folks to swallow Pargyline Hydrochloride with water, once or twice daily. Food usually doesn't interfere much, but some foods can change how the body handles MAOIs. Eating aged cheese, cured meats, or fermented foods may trigger a big spike in blood pressure, sometimes called a hypertensive crisis. That high can mean headaches, pounding heart, and even a risk for stroke — nothing anyone would want.
Pargyline Hydrochloride can clash with quite a few other medicines or supplements. Cold remedies, certain painkillers, antidepressants, and herbal products can set off dangerous reactions. Serotonin syndrome, which brings confusion, stiffness, fever, and seizures, often links back to mixing meds by mistake. Reporting everything taken, even rarely, keeps doctors in the loop and avoids nasty surprises.
Folks using MAOIs need to keep close tabs on blood pressure. It’s not enough to go by how you feel. High blood pressure doesn’t always cause symptoms early on. At home, an automatic cuff helps, but nothing beats checking in with a doctor, especially after any changes in other drugs or diet.
Staying on a strict schedule keeps blood pressure steady. If a dose gets skipped, better to take it as soon as noticed, as long as the next one isn’t right around the corner. Double doses wreck routines and risk bad side effects. If uncertainty creeps in, turning to a pharmacist or doctor is smarter than self-correcting.
Handing out a prescription can’t match the value of two-way conversations. Patients should never hesitate to ask about side effects, diet, or how long to expect results. Health care teams know the latest research and can share tips, like how to read labels for hidden risky ingredients. Armed with real info, people can avoid the worst pitfalls.
Many people now lean on pharmacists, nurses, and even smart apps to remember medicines and track symptoms. With support, the chance for mishaps drops and motivation to stick with the plan rises. Managing blood pressure means more than taking a daily pill — it also takes honest conversations, steady routines, and the courage to ask for help.
Pargyline Hydrochloride made a mark years ago for helping people manage high blood pressure. It blocks an enzyme called monoamine oxidase (MAO-B), changing the way the body breaks down certain chemicals in the brain. Because Pargyline influences these chemical signals, taking it with other medications can open the door for serious problems — sometimes even life-threatening ones.
Some years ago, I met a patient dealing with high blood pressure. He was frustrated, trying different approaches. One overlooked factor: the mix of medications he took. On Pargyline, he added a cold pill from the local pharmacy. His heart raced, and his blood pressure shot up. It’s easy to see how things can snowball when we underestimate how old medicines like Pargyline fit together with everyday drugs. He got lucky, but not everyone does. Mixing certain drugs with Pargyline is a risk that often gets hidden under the medical jargon.
Mixing antidepressants that boost serotonin, such as SSRIs or tricyclics, with Pargyline can spark serotonin syndrome. This throws the body into confusion: agitation, high fever, even seizures are possible. Medications for Parkinson’s, like levodopa, can also clash with Pargyline, exaggerating both benefits and side effects. Not only that, but drugs for colds, allergy relief, or coughs sometimes carry adrenaline-like compounds. Together with Pargyline, these can send blood pressure spiraling or trigger heart rhythm issues. Even some painkillers, sleep aids, or appetite suppressants hold risks when paired with this medication.
The risk doesn’t stop with prescription pills. Over-the-counter cough medicines or nose sprays can trigger dangerous spikes in blood pressure. Certain antibiotics and anesthetics used in surgery might also tip the chemical scales. People using Pargyline need to alert every healthcare provider, even at the dentist’s office.
Monoamine oxidase inhibitors (MAOIs) like Pargyline send another warning: avoid foods rich in tyramine. Think aged cheeses, cured meats, soy sauce, or fermented products. Eating these along with MAOIs lets tyramine build up, upping the risk for a “cheese reaction”—sudden headaches, chest pain, and dangerously high blood pressure. This advice sometimes gets lost in the shuffle, especially for younger generations who rarely see MAOIs prescribed.
With safer blood pressure treatments now available, doctors don’t hand out Pargyline as much anymore, but some older patients still rely on it. Sometimes it crops up in research settings. Doctors need up-to-date records on what patients are taking — not just prescription drugs, but everything down to herbal supplements and vitamins. Electronic health records can help flag risky combinations, but nothing beats a frank conversation. Pharmacists play a big role too, asking the right questions and warning about both food and drug traps that come with older medications.
Understanding the risks surrounding Pargyline takes more than a list of dos and don’ts. Open communication, attention to diet, and a careful look at other medicines make all the difference. For those who still have this drug in their medicine cabinet, a quick talk with the pharmacist can prevent disaster.
Pargyline Hydrochloride entered the medical scene in the past century as a treatment for high blood pressure. This drug belongs to a group called monoamine oxidase inhibitors, or MAOIs. These medications work by changing the balance of certain chemicals in the brain and the rest of the body, which in turn affects blood pressure and mood. Not every medication fits every person, and some folks have real reasons to steer clear of pargyline.
Pargyline Hydrochloride blocks an enzyme that is involved in breaking down certain neurotransmitters. On paper, that sounds useful. In practice, folks with a history of certain health issues face real risks. Anyone with problems like pheochromocytoma—a tumor on the adrenal gland—can experience life-threatening spikes in blood pressure with pargyline. People with cardiovascular conditions, such as recent heart attacks, heart failure, or irregular heartbeats, risk major complications. The drug can push already fragile systems over the edge due to its effects on the way the body controls blood pressure and heart rhythm.
Anyone living with mental health challenges such as depression or bipolar disorder should tread with care. Mixing pargyline with other antidepressants—especially SSRIs, tricyclics, or even over-the-counter medications for mood—may trigger serotonin syndrome. This is a medical emergency marked by confusion, fever, and sometimes deadly changes in body functions. Drug interaction is not limited to psychiatric medications, either. Decongestants, weight loss supplements, and even some painkillers bought at any pharmacy can mix poorly with pargyline and create serious problems.
Not all risks come from other drugs. Pargyline, like other MAOIs, affects the way the body handles tyramine. Tyramine pops up in aged cheeses, cured meats, soy, draft beers, and other fermented foods. If someone has trouble sticking to dietary limits because of memory challenges or lack of information, their risk rises. Eating these foods can make blood pressure skyrocket, which has landed more than a few patients in the emergency room. This isn’t just a quirky warning on the package. It’s a real, everyday concern. Folks not willing or able to keep a strict diet should consider another treatment route.
Expecting mothers and those breastfeeding face unknowns since this drug’s effect on babies has not been studied in depth. The safest bet is to find options with proven safety profiles for both parent and child. Children and teens should also avoid pargyline. Developing bodies and brains respond differently, and no reliable information proves this drug does more good than harm for young people. For older adults, especially those with multiple prescriptions, the web of possible drug interactions grows complicated fast.
Current guidelines stand for a reason. Doctors moved away from prescribing pargyline often due to these complications. Newer blood pressure medicines and antidepressants come with fewer food rules and less risk of deadly interactions. Regular conversations with healthcare providers open the door to safer, more practical alternatives. Blood tests, honest disclosure of all medications, and lifestyle checks help build a treatment plan that works without adding unneeded hazard.
| Names | |
| Preferred IUPAC name | N-methyl-N-prop-2-ynyl-3-phenylpropane-1-amine hydrochloride |
| Other names |
Eutonyl Pargyline HCl Pargyline hydrochloridum NSC-63215 |
| Pronunciation | /ˈpɑːr.dʒɪ.laɪn haɪˌdrɒ.kləˈraɪd/ |
| Identifiers | |
| CAS Number | 555-57-7 |
| Beilstein Reference | 1044623 |
| ChEBI | CHEBI:8062 |
| ChEMBL | CHEMBL1400 |
| ChemSpider | 1689 |
| DrugBank | DB00852 |
| ECHA InfoCard | 100.096.071 |
| EC Number | 222-140-9 |
| Gmelin Reference | 21222 |
| KEGG | D08374 |
| MeSH | D010275 |
| PubChem CID | 60948 |
| RTECS number | **MW9400000** |
| UNII | BQW44B6N9F |
| UN number | UN2811 |
| Properties | |
| Chemical formula | C11H13N·HCl |
| Molar mass | 282.22 g/mol |
| Appearance | White to off-white crystalline powder |
| Odor | Odorless |
| Density | 1.2 g/cm³ |
| Solubility in water | Soluble in water |
| log P | 1.45 |
| Acidity (pKa) | 12.90 |
| Basicity (pKb) | 4.05 |
| Magnetic susceptibility (χ) | -57.0e-6 cm^3/mol |
| Refractive index (nD) | 1.583 |
| Dipole moment | 3.01 D |
| Pharmacology | |
| ATC code | N04BD01 |
| Hazards | |
| Main hazards | Harmful if swallowed, causes skin and eye irritation, may cause respiratory irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS06,GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332 |
| Precautionary statements | P264, P270, P273, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-2-0 |
| Flash point | > 230 °C |
| Autoignition temperature | 410°C |
| Lethal dose or concentration | Rat oral LD50 205 mg/kg |
| LD50 (median dose) | LD50 (median dose): Rat oral 215 mg/kg |
| NIOSH | PY2625000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.01-0.1% |
| Related compounds | |
| Related compounds |
Phenelzine Tranylcypromine Selegiline Rasagiline Isocarboxazid Moclobemide Clorgyline |
